Close

Brainstorm Cell Therapeutics (BCLI) Reports Positive Topline Data in Phase 2 Study Evaluating NurOwn as Treatment for Progressive MS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. IBM
4. HCP
5. PI
6. LRCX
7. BIIB
8. CNMD
9. BSX
10. ASGN


Go back to Brainstorm Cell Therapeutics (BCLI) Reports Positive Topline Data in Phase 2 Study Evaluating NurOwn as Treatment for Progressive MS

Brainstorm Cell Therapeutics (BCLI) Climbs 27% Following Positive Topline Data in Phase 2 Study Evaluating NurOwn as Treatment for Progressive MS

March 24, 2021 7:50 AM EDT

Brainstorm Cell Therapeutics (NASDAQ: BCLI) Climbs 27% Following Positive Topline Data in Phase 2 Study Evaluating NurOwn as Treatment for Progressive MS

Earlier BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced topline data from the Company's Phase 2 trial evaluating three repeated... More